CN104114686A - Sanfilippo综合征的生物标志物及其用途 - Google Patents

Sanfilippo综合征的生物标志物及其用途 Download PDF

Info

Publication number
CN104114686A
CN104114686A CN201280065796.8A CN201280065796A CN104114686A CN 104114686 A CN104114686 A CN 104114686A CN 201280065796 A CN201280065796 A CN 201280065796A CN 104114686 A CN104114686 A CN 104114686A
Authority
CN
China
Prior art keywords
biomarkers
level
sanfilippo syndrome
treatment
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280065796.8A
Other languages
English (en)
Chinese (zh)
Inventor
P·哈斯利特
C·理查德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of CN104114686A publication Critical patent/CN104114686A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
CN201280065796.8A 2011-11-07 2012-11-07 Sanfilippo综合征的生物标志物及其用途 Pending CN104114686A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556810P 2011-11-07 2011-11-07
US61/556,810 2011-11-07
US201261584165P 2012-01-06 2012-01-06
US61/584,165 2012-01-06
PCT/US2012/063935 WO2013070760A1 (en) 2011-11-07 2012-11-07 Biomarkers for sanfilippo syndrome and uses thereof

Publications (1)

Publication Number Publication Date
CN104114686A true CN104114686A (zh) 2014-10-22

Family

ID=48280853

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280065796.8A Pending CN104114686A (zh) 2011-11-07 2012-11-07 Sanfilippo综合征的生物标志物及其用途

Country Status (7)

Country Link
US (2) US20130121984A1 (enExample)
EP (1) EP2776553B1 (enExample)
JP (1) JP2015504514A (enExample)
CN (1) CN104114686A (enExample)
AU (1) AU2012335890A1 (enExample)
CA (1) CA2854333A1 (enExample)
WO (1) WO2013070760A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112578123A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015012767A2 (pt) * 2012-12-07 2017-09-12 Shire Human Genetic Therapies métodos e composições para tratamento intratecal administrado de mucupolisacaridose tipo iiia
AU2015323966A1 (en) * 2014-09-29 2017-03-16 Alexion Pharmaceuticals, Inc. Methods of treating mucopolysaccharidosis IIIB (MPSIIIB)
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
WO2017132675A1 (en) * 2016-01-29 2017-08-03 Alexion Pharmaceuticals, Inc. Enzyme replacement therapy in mucopolysaccharidosis iiib patients
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048047A1 (en) * 2003-08-29 2005-03-03 Kakkis Emil D. Delivery of therapeutic compounds to the brain and other tissues
US20090092996A1 (en) * 2005-12-08 2009-04-09 Clarke Lorne A Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith
US20100184013A1 (en) * 2009-01-02 2010-07-22 Zacharon Pharmaceuticals, Inc. Detection of oligosaccharides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US20050055733A1 (en) * 2001-07-06 2005-03-10 Zairen Sun Small intestine and colon genes
US7951545B2 (en) * 2002-04-30 2011-05-31 Seikagaku Corporation Method for detecting lysosomal storage diseases
AUPS293002A0 (en) * 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP4965999B2 (ja) * 2005-12-27 2012-07-04 セント ルイス ユニバーシティ ムコ多糖症の診断方法
WO2010078515A2 (en) * 2009-01-02 2010-07-08 Zacharon Pharmaceuticals, Inc. Polymer end group detection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048047A1 (en) * 2003-08-29 2005-03-03 Kakkis Emil D. Delivery of therapeutic compounds to the brain and other tissues
US20090092996A1 (en) * 2005-12-08 2009-04-09 Clarke Lorne A Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith
US20100184013A1 (en) * 2009-01-02 2010-07-22 Zacharon Pharmaceuticals, Inc. Detection of oligosaccharides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IGOR NESTRASIL ET AL.: "Brain volumes and cognitive function in MPS IIIA: Cross-sectional study", 《MOLECULAR GENETICS AND METABOLISM》, vol. 102, no. 2, 28 February 2011 (2011-02-28) *
赵小媛等: "尿粘多糖定量测定及其临床应用", 《中国儿童保健杂志》, vol. 18, no. 11, 30 November 2010 (2010-11-30) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112578123A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
CN112578123B (zh) * 2019-09-27 2022-10-25 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途

Also Published As

Publication number Publication date
EP2776553B1 (en) 2018-07-11
US20170131293A1 (en) 2017-05-11
EP2776553A1 (en) 2014-09-17
JP2015504514A (ja) 2015-02-12
EP2776553A4 (en) 2015-05-27
AU2012335890A1 (en) 2014-05-29
CA2854333A1 (en) 2013-05-16
WO2013070760A1 (en) 2013-05-16
US20130121984A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
Etter et al. Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study
EP2776553B1 (en) Biomarkers for sanfilippo syndrome and uses thereof
JP6707181B2 (ja) 早産のリスクがある妊娠女性を同定するためのキットまたはパッケージ、および、当該キットまたはパッケージの使用
CN114410773B (zh) 用于预测或诊断抑郁症复发的标志物组合及其应用
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
EP3327134A1 (en) Method and biomarkers for in vitro diagnosis of mental disorders
WO2021228125A1 (en) Protein markers for assessing alzheimer's disease
US20250314645A1 (en) Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury
JP6663936B2 (ja) 胎児性アルコール症候群により引き起こされる障害の診断方法
Cao et al. Analysis of cases with cerebrospinal fluid characteristics similar to tuberculous meningitis
Epstein et al. Subventricular zone stem cell niche injury is associated with intestinal perforation in preterm infants and predicts future motor impairment
US8372594B2 (en) Secreted phospholipase A2 biomarkers for arthritis
US20140221235A1 (en) Biomarker algorithm for determining the time of stroke symptom onset and method
US20250101519A1 (en) Use of hypoxia-inducible factor 1 alpha as marker in depression recurrence diagnosis
US20120208718A1 (en) Schizophrenia treatment response biomarkers
KR102781029B1 (ko) 경도인지장애 진단을 위한 신규 바이오마커 패널과 알츠하이머 치매 전환 예측 단백질 바이오마커 및 이를 이용한 초기 치매 치료의 최적 환자군 선별을 위한 동반진단용 조성물
US20250250635A1 (en) Kit and method for determining presence or absence of affection of dementia
US20150309053A1 (en) Test method and test kit for psychiatric ailments
Raghavendra et al. Anubhuti. Can serum biomarkers prognosticate out come of traumatic brain injury (TBI)
KR20240173248A (ko) 알레르기비염 발생 여부 또는 발생 시기 예측 또는 진단용 조성물, 진단 키트, 정보제공방법 및 알레르기비염 예방 또는 치료제 선별방법
Isaacs Pathophysiology and Proteogenomics of Post-infectious and Post-hemorrhagic Hydrocephalus in Infants
WO2022011269A2 (en) Biofluid-based protein and mirna biomarkers for neonatal hypoxic-ischemic encephalopathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141022

RJ01 Rejection of invention patent application after publication